Melatonin is NOT a standard or guideline-recommended therapy for melanoma
Based on current evidence-based guidelines, melatonin should not be used as treatment for melanoma outside of clinical trials. No major melanoma treatment guideline (ASCO, ESMO, NCCN, or SITC) recommends melatonin as part of standard care for any stage of melanoma 1, 2, 3.
Why Melatonin Is Not Recommended
Guideline Evidence
The most recent and authoritative melanoma guidelines make no mention of melatonin as a therapeutic option:
- ASCO 2023 Guidelines 3: Recommend immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) and BRAF/MEK inhibitors for both adjuvant and metastatic settings, with no role for melatonin
- ASCO 2020 Guidelines 1: Comprehensive systematic review of melanoma therapies identified no role for melatonin in standard care
- SITC 2018 Consensus 2: Detailed immunotherapy recommendations with no mention of melatonin as adjunctive or primary therapy
Research Evidence Shows Mixed and Insufficient Results
While some preclinical and small clinical studies suggest potential benefit, the evidence is inadequate for clinical use:
The only positive clinical data comes from a small 1996 study 4 of 30 node-relapsed melanoma patients showing improved disease-free survival with melatonin 20 mg/day as adjuvant therapy. However, this single small study from nearly 30 years ago has never been validated in larger trials.
More recent clinical data is negative: A 2021 randomized trial 5 of 57 patients with disseminated melanoma found that adding melatonin 3 mg daily to dacarbazine chemotherapy provided no benefit in objective response rate (7% across all groups), time to progression (57 days), or overall survival (236-422 days, p=0.712).
Preclinical data shows concerning complexity: Animal studies 6 demonstrate that melatonin's effects are highly dependent on circadian timing. When administered during circadian disruption (continuous light conditions), melatonin actually increased tumor malignancy and reduced survival in melanoma-bearing mice, despite improving outcomes under normal light-dark cycles.
Current Standard of Care
For melanoma treatment, use evidence-based therapies:
Adjuvant Setting (Resected Disease)
- Stage IIB-C: Pembrolizumab or nivolumab 3
- Stage IIIA/B/C/D (BRAF wild-type): Nivolumab or pembrolizumab 1
- Stage IIIA/B/C/D (BRAF-mutant): Nivolumab, pembrolizumab, or dabrafenib/trametinib 1
Metastatic/Unresectable Disease
- BRAF wild-type: Ipilimumab plus nivolumab, nivolumab alone, or pembrolizumab alone 1, 3
- BRAF-mutant: Same immunotherapy options OR BRAF/MEK inhibitor combinations (dabrafenib/trametinib, encorafenib/binimetinib, vemurafenib/cobimetinib) 1
Clinical Trial Context Only
If considering melatonin, it should only be within a clinical trial setting. An ongoing phase III trial (AMUM) 7 is investigating adjuvant melatonin 20 mg daily for 5 years in uveal melanoma, but results are not yet available. This represents appropriate investigation of melatonin's potential role, but does not support current clinical use.
Important Caveats
- Melatonin's effects appear highly dependent on circadian timing and may be harmful if administered incorrectly 6
- The hormone shows variable expression of its receptors (MTNR1A, MTNR1B) in melanoma tissues 8
- Combination with standard chemotherapy has failed to show benefit 5
- Preclinical anti-cancer mechanisms (immune modulation, anti-proliferation, apoptosis induction) 9, 10 have not translated to meaningful clinical outcomes
Bottom line: Use guideline-recommended immunotherapy or targeted therapy for melanoma. Reserve melatonin for clinical trials only, where proper circadian timing, dosing, and patient selection can be rigorously evaluated.